Dihexa in Clinical Trials: What We've Learned So Far The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York The Peptide Craze Ground Truths CDER Brings Many Safe and Effective Therapies to Patients and Consumers in 2024 FDA